Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Operating Margin (2016 - 2025)

Historic Operating Margin for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 52.36%.

  • Karyopharm Therapeutics' Operating Margin rose 500600.0% to 52.36% in Q4 2025 from the same period last year, while for Dec 2025 it was 62.1%, marking a year-over-year increase of 201400.0%. This contributed to the annual value of 62.1% for FY2025, which is 201400.0% up from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Operating Margin is 52.36%, which was up 500600.0% from 34.56% recorded in Q3 2025.
  • Karyopharm Therapeutics' Operating Margin's 5-year high stood at 37.19% during Q4 2021, with a 5-year trough of 225.16% in Q1 2021.
  • In the last 5 years, Karyopharm Therapeutics' Operating Margin had a median value of 86.07% in 2022 and averaged 92.27%.
  • Examining YoY changes over the last 5 years, Karyopharm Therapeutics' Operating Margin showed a top increase of 1526100bps in 2022 and a maximum decrease of -1380500bps in 2022.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Operating Margin stood at 37.19% in 2021, then plummeted by -371bps to 100.86% in 2022, then fell by -11bps to 112.03% in 2023, then rose by 9bps to 102.42% in 2024, then soared by 49bps to 52.36% in 2025.
  • Its Operating Margin stands at 52.36% for Q4 2025, versus 34.56% for Q3 2025 and 64.3% for Q2 2025.